Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD (4519)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Chugai Pharmaceutical Co., Ltd. - Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 10:13am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Galderma, Nestle Skin Health's Medical Solutions Business issued a press release regarding the results of phase 2b study of nemolizumab (CIM331) created by Chugai in patients with moderate-to-severe atopic dermatitis to investigate the efficacy and safety of nemolizumab.

Please refer to the link below for details of the press release: Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

https://www.nestleskinhealth.com/news/galderma-announces-positive-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO LTD -0.90% 6620 End-of-day quote.7.12%
NESTLÉ 0.21% 84.36 Delayed Quote.5.51%
ROCHE HOLDING -0.70% 254 Delayed Quote.6.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHUGAI PHARMACEUTICAL CO L
01/21CHUGAI PHARMACEUTICAL : Files an Application for Expanded Use of Genomic Mutatio..
AQ
01/11CHUGAI PHARMACEUTICAL : MI Chat, a ChatBot for Healthcare Professionals, Starts ..
AQ
01/09Completion of Transfer of Marketing and Manufacturing Rights of 13 Long-Term ..
AQ
01/03Viela planning BLA submission for inebilizumab in rare CNS disorder
AQ
2018CHUGAI PHARMACEUTICAL : Obtains Approval for Genomic Mutation Analysis Program '..
AQ
2018CHUGAI PHARMACEUTICAL CO LTD : Ex-dividend day for final dividend
FA
2018CHUGAI PHARMACEUTICAL : Satralizumab Meets Primary Endpoint in Phase III Monothe..
AQ
2018CHUGAI PHARMACEUTICAL : Files a New Drug Application for a ROS1/TRK Inhibitor En..
AQ
2018CHUGAI PHARMACEUTICAL : Chugais Satralizumab Meets Primary Endpoint in Phase III..
AQ
2018CHUGAI PHARMACEUTICAL : Chugais Satralizumab Receives FDA Breakthrough Therapy D..
AQ
More news
Financials (JPY)
Sales 2018 573 B
EBIT 2018 -
Net income 2018 90 595 M
Finance 2018 216 B
Yield 2018 1,06%
P/E ratio 2018 40,16
P/E ratio 2019 32,75
EV / Sales 2018 6,15x
EV / Sales 2019 5,63x
Capitalization 3 739 B
Chart CHUGAI PHARMACEUTICAL CO LTD
Duration : Period :
Chugai Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 6 833  JPY
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Manager-R&D Portfolio Management Department
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD7.12%34 161
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
MERCK AND COMPANY-0.71%197 291